Heparegenix
Preclinical stage company developing novel therapies for the treatment of acute and chronic liver diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | €21.5m | Late VC | |
| Total Funding | 000k | ||
Related Content
HepaRegeniX is a biotechnology company focused on discovering and developing innovative drug candidates to treat multiple liver diseases. The company's primary market includes healthcare providers, pharmaceutical companies, and research institutions. HepaRegeniX operates in the biotechnology and pharmaceutical sectors, targeting unmet medical needs in liver disease treatment. The business model revolves around the research and development of proprietary drug candidates, which are then advanced through clinical trials. Revenue is generated through funding rounds, partnerships, and potential future licensing deals or sales of developed drugs. Recently, HepaRegeniX raised a Series C funding round to further the clinical development of its lead candidate, HRX 215, aimed at liver regeneration.
Keywords: biotechnology, liver disease, drug development, clinical trials, healthcare, pharmaceutical, liver regeneration, HRX 215, Series C funding, innovation.